InBody Band 3 Fitness Tracker to Improve Health Outcomes and Quality of Life in Black Prostate Cancer Survivors

NCT06703996 | Completed

• 2 other identifiers: 24-009203NCI-2024-09282
• Study Type: interventional
• Target: 13
• Locations: 1 country
• Sites: 2

Brief Summary

This clinical trial studies how well the InBody Band 3 fitness tracker works to improve physical activity, body composition, and quality of life in Black prostate cancer survivors. Prostate cancer is the most common cancer in men and Black men are more likely to be diagnosed with prostate cancer in an advanced stage. Body composition is associated with disease progression, treatment response, and survival in cancer patients. Reducing stress and maintaining healthy levels of physical activity and sleep are important for a healthy body and improving outcomes, however, there is currently little evidence available on the physical activity, stress levels and sleep patterns in this population. Wearable health activity trackers and smart watches are tools that can be used to track physical activity, stress, sleep and body composition and have been shown to have a positive impact in many patient populations. The InBody Band 3 may be an effective method to improve physical activity, body composition and quality of life in Black prostate cancer survivors.

Conditions

Prostate Carcinoma

Outcome Measures

Primary Outcomes (2)

• Adherence rate

  The adherence rate will be calculated as the ratio of number of valid data collection weeks to the number of expected valid data collection weeks for each participant. A group average adherence rate of 80% will be considered feasible.

  Up to 6 weeks

• Change in acceptability scale score

  Will be assessed using the 6-item Acceptability survey for physical activity interventions. Participants will be asked to rate each question from 0 (not at all) to 10 (extremely), and a mean score will be calculated. An average group rating of 8.0 or higher on a 10-point scale will be required to determine intervention acceptability. Change in score will be defined as the final intervention week's value minus the first week's value.

  Up to 8 weeks

Study Arms (1)

Supportive care (InBody Band 3 fitness tracker)

EXPERIMENTAL

Patients wear the InBody Band 3 fitness tracker continuously and participate in check-in/goal-setting discussions over 20-30 minutes weekly for 6 weeks.

Other: Discussion; Other: Medical Device Usage and Evaluation; Other: Questionnaire Administration

Interventions

Discussion OTHER

Participate in check-in/goal-setting discussions

Also known as: Discuss

Supportive care (InBody Band 3 fitness tracker)

Medical Device Usage and Evaluation OTHER

Wear the InBody Band 3 fitness tracker

Supportive care (InBody Band 3 fitness tracker)

Questionnaire Administration OTHER

Ancillary studies

Supportive care (InBody Band 3 fitness tracker)

Eligibility Criteria

• Age: 18 Years+
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Able to read/speak English and are able to communicate by phone
• years of age or older
• Self-identify as Black
• Have been diagnosed with stage I-IV prostate cancer
• Have an active email address and are able to regularly check emails for electronic surveys
• Own and are willing to use a personal smartphone with regular/reliable access to the internet to sync regularly with a fitness tracker
• Are willing to wear and use a smart fitness tracker for 6 weeks and allow sharing of their fitness data with the study team
• Are not currently undergoing adjunct cancer therapy (e.g. chemotherapy, radiation) during the 6 weeks of study participation, except oral tyrosine kinase inhibitor or hormonal therapies; and
• Are an existing Mayo patient
• Self-report that they would like to improve their physical activity during initial study coordinator contact

You may not qualify if:

• Live outside of the United States (U.S)
• Have an implanted medical device (e.g., pacemaker, etc.) or a life-sustaining device (e.g., patient monitoring device)
• Have a self-reported history of a psychiatric disorder(s) or moderate to severe cognitive impairment precluding participation in the study intervention or preventing the ability to provide independent informed consent
• Are on prolonged bed rest (i.e., more than half of the waking day in bed) by self-report
• Currently have any lower extremity injury that impedes them from engaging in walking for one block
• Are unable to walk for at least one block without a walking aide by self-report; or
• Regularly use a wheelchair for mobility by self-report

Sponsors & Collaborators

• Mayo Clinic: lead

Study Sites (2)

Mayo Clinic in Florida

Jacksonville, Florida, 32224-9980, United States

Location

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

Location

Related Links

• Mayo Clinic Clinical Trials

MeSH Terms

Conditions

Prostatic Neoplasms

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases

Study Officials

• Emma Fortune Ngufor, PhD

  Mayo Clinic in Rochester

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: DEVICE FEASIBILITY
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: November 15, 2024
• First Posted: November 25, 2024
• Study Start: November 4, 2024
• Primary Completion: May 8, 2025
• Study Completion: May 8, 2025
• Last Updated: September 3, 2025

Record last verified: 2025-08

Locations

US (2)